|
gptkbp:instanceOf
|
drug
|
|
gptkbp:activeDuring
|
alogliptin_benzoate
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
Nesina
|
|
gptkbp:chemicalFormula
|
C17H21N5O
|
|
gptkbp:clinicalTrials
|
combination therapy
Phase III
monotherapy
|
|
gptkbp:commonName
|
25 mg once daily
|
|
gptkbp:contraindication
|
hypersensitivity to alogliptin
|
|
gptkbp:developer
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:dosageForm
|
tablet
|
|
gptkbp:drugInterdiction
|
antidiabetic agent
increases incretin levels
bioavailability 100%
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Alogliptin
|
|
gptkbp:interactsWith
|
warfarin
other antidiabetic medications
digoxin
|
|
gptkbp:lastProduced
|
2013
|
|
gptkbp:mandates
|
improve glycemic control
|
|
gptkbp:marketedAs
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:nutritionalValue
|
liver
|
|
gptkbp:operates_in
|
A10BH05
|
|
gptkbp:patentExpiration
|
2026
|
|
gptkbp:researchAreas
|
diabetes management
|
|
gptkbp:route
|
oral
|
|
gptkbp:safetyFeatures
|
Category B
|
|
gptkbp:sideEffect
|
headache
hypoglycemia
nasopharyngitis
|
|
gptkbp:triggerType
|
DPP-4 inhibitor
|
|
gptkbp:usedFor
|
type 2 diabetes
|
|
gptkbp:variant
|
insulin
metformin
sulfonylureas
|
|
gptkbp:waterManagement
|
urine
|